share_log

HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Maintains $10 Price Target

Benzinga ·  Jan 9 00:24  · Ratings

HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment